Compare Ascendis Pharma A/S (ASND) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs UnitedHealth Group Inc — how do they compare? Ascendis Pharma A/S trades at $263.88 (market cap $17.74B), while UnitedHealth Group Inc trades at $428.88 (market cap $385.62B). The key difference: UnitedHealth Group Inc is far larger — about 21.7× Ascendis Pharma A/S's market cap, and UnitedHealth Group Inc pays a 2.19% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | UNH | |
|---|---|---|
Market Cap | $17.74B | $385.62B |
Sector | Health | Health |
52-Week High | $277.18 | $431.68 |
52-Week Low | $163.32 | $237.77 |
Enterprise Value | $18.11B | $432.30B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, slightly above the analyst consensus price target of $423.18. The stock shows bullish technical signals with strong moving average support and recent earnings beats in three consecutive quarters. Revenue has grown consistently from $322.1B in 2022 to $447.6B in 2025, though net income margin has compressed from 6.24% to 2.69% over the same period. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns through dividends and buybacks.
Outlook remains positive with 82.7% analyst buy ratings and strong institutional support, driven by aging demographics and healthcare innovation. Key risks include regulatory scrutiny (Massachusetts Medicaid lawsuit filed May 29, 2026), margin pressure from rising costs, and increasing debt levels. The current P/E of 31.97 appears elevated relative to historical norms, suggesting valuation sensitivity to earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
